HORMAD1 Gene as A Potential Cancer Drug Target (G84072)

Target Name: HORMAD1

NCBI ID: G84072

HORMAD1

HORMAD1 Gene as A Potential Cancer Drug Target

The HORMAD1 gene is a protein that is located in the human chromosome 17q11 region. It is a gene that encodes a protein known as HORMA, which is a type of nuclear receptor that is involved in a variety of physiological processes in the body. HORMAD1 is a splice variant gene that has four different transcript variants.

The HORMA receptor is a transmembrane protein that is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. It is a protein that is composed of four distinct domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a nuclear domain. The extracellular domain of HORMA is involved in the formation of the receptor complex, the transmembrane domain is involved in the formation of the receptor channel, the intracellular domain is involved in the interaction with intracellular signaling pathways, and the nuclear domain is involved in the regulation of gene expression.

HORMAD1 is a gene that has been identified as a potential drug target in the field of cancer. Studies have shown that HORMAD1 is highly expressed in a variety of cancer types, including breast, ovarian, and prostate cancers. Additionally, HORMAD1 has been shown to be involved in the regulation of cellular processes that are associated with cancer progression, such as cell survival, angiogenesis, and metastasis.

One of the potential reasons why HORMAD1 is a drug target is because of its involvement in the regulation of cell growth and differentiation. Studies have shown that HORMAD1 is involved in the regulation of cell proliferation and cell differentiation, and that it plays a role in the development of cancer. Additionally, HORMAD1 has been shown to be involved in the regulation of cell survival, and that it may be a useful target for drugs that are designed to inhibit cell survival.

Another potential reason why HORMAD1 is a drug target is because of its involvement in the regulation of angiogenesis and metastasis. Studies have shown that HORMAD1 is involved in the regulation of angiogenesis, the formation of new blood vessels, and the development of cancer metastasis. Additionally , HORMAD1 has been shown to be involved in the regulation of cell adhesion and migration, and that it may be a useful target for drugs that are designed to inhibit these processes.

In conclusion, HORMAD1 is a gene that has been identified as a potential drug target in the field of cancer. Its involvement in the regulation of cell growth, differentiation, angiogenesis, and metastasis makes it a promising target for drugs that are designed to inhibit these processes. Further research is needed to determine the full extent of HORMAD1's role as a drug target and to develop effective treatments for cancer.

Protein Name: HORMA Domain Containing 1

Functions: Plays a key role in meiotic progression. Regulates 3 different functions during meiosis: ensures that sufficient numbers of processed DNA double-strand breaks (DSBs) are available for successful homology search by increasing the steady-state numbers of single-stranded DSB ends. Promotes synaptonemal-complex formation independently of its role in homology search. Plays a key role in the male mid-pachytene checkpoint and the female meiotic prophase checkpoint: required for efficient build-up of ATR activity on unsynapsed chromosome regions, a process believed to form the basis of meiotic silencing of unsynapsed chromatin (MSUC) and meiotic prophase quality control in both sexes

The "HORMAD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HORMAD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets